Treatment of chronic hepatitis B with nucleos(t)ide analogues
-
- OHISHI Waka
- Department of Clinical Studies, Radiation Effects Research Foundation
-
- CHAYAMA Kazuaki
- Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University
Search this Article
Author(s)
-
- OHISHI Waka
- Department of Clinical Studies, Radiation Effects Research Foundation
-
- CHAYAMA Kazuaki
- Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University
Journal
-
- Hepatology research : the official journal of the Japan Society of Hepatology
-
Hepatology research : the official journal of the Japan Society of Hepatology 42(3), 219-225, 2012-03-01
References: 35
-
1
- Chronic hepatitis B : update 2009
-
LOK AS
Hepatology 50, 1-36, 2009
Cited by (1)
-
2
- Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B
-
LAI CL
Clin Infect Dis 36, 687-696, 2003
Cited by (1)
-
3
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy
-
TENNEY DJ
Hepatology 49, 1503-1514, 2009
Cited by (1)
-
4
- Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection
-
YOKOSUKA O
J Hepatol 52, 791-799, 2010
Cited by (1)
-
5
- A treatment algorithm for the management of chronic hepatitis B virus infection in the United States : 2008 update
-
KEEFFE EB
Clin Gastroenterol Hepatol 6, 1315-1341, 2008
Cited by (1)
-
6
- Updated definitions of healthy ranges for serum alanine aminotransferase levels
-
PRATI D
Ann Intern Med 137, 1-10, 2002
Cited by (1)
-
7
- Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study
-
KARIV R
Liver Int 26, 445-450, 2006
Cited by (1)
-
8
- Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
-
CHAYAMA K
Hepatology 27, 1711-1716, 1998
Cited by (1)
-
9
- Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping
-
OHISHI W
J Med Virol 72, 558-565, 2004
Cited by (1)
-
10
- Viral kinetics in patients with chronic hepatitis B during lamivudine therapy by real-time PCR
-
OHISHI W
Acta Hepatol Jpn 43, 214, 2002
Cited by (1)
-
11
- Entecavir resistance is rare in nucleoside naive patients with hepatitis B
-
COLONNO RJ
Hepatology 44, 1656-1665, 2006
Cited by (1)
-
12
- Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
-
NAFA S
Hepatology 32, 1078-1088, 2000
Cited by (1)
-
13
- Long-term therapy of chronic hepatitis B with lamivudine
-
LAU DT
Hepatology 32, 828-834, 2000
Cited by (1)
-
14
- Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan
-
ORITO E
Hepatology 34, 590-594, 2001
Cited by (1)
-
15
- Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease
-
SUMI H
Hepatology 37, 19-26, 2003
Cited by (1)
-
16
- Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan
-
SAKUGAWA H
J Med Virol 67, 484-489, 2002
Cited by (1)
-
17
- Hepatitis B virus genotypes and hepatocellular carcinoma in Japan
-
ORITO E
Intervirology 46, 408-412, 2003
Cited by (1)
-
18
- Hepatitis B genotypes and the response to interferon therapy
-
KAO JH
J Hepatol 33, 998-1002, 2000
Cited by (1)
-
19
- HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C
-
WAI CT
Hepatology 36, 1425-1430, 2002
Cited by (1)
-
20
- Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients
-
LI X
J Clin Microbiol 48, 4363-4369, 2010
Cited by (1)
-
21
- A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D
-
TANAKA Y
Hepatology 40, 747-755, 2004
Cited by (1)
-
22
- Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load
-
KIMURA T
J Clin Microbiol 40, 439-445, 2002
Cited by (1)
-
23
- Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen ; a marker distinct from viral DNA for monitoring lamivudine treatment
-
ROKUHARA A
J Viral Hepat 10, 324-330, 2003
Cited by (1)
-
24
- Drug therapy : tenofovir
-
LOK AS
Hepatology 52, 743-747, 2010
Cited by (1)
-
25
- Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy : two-year follow-up
-
YATSUJI H
J Hepatol 48, 923-931, 2008
Cited by (1)
-
26
- Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues
-
VAN BOMMEL F
Hepatology 51, 73-80, 2010
Cited by (1)
-
27
- Successful treatment of an entecavir-resistant hepatitis B virus variant
-
YATSUJI H
J Med Virol 79, 1811-1817, 2007
Cited by (1)
-
28
- Research of hepatitis overcome urgent strategy
-
KUMADA H
Research report of the standardization of viral hepatitis treatment including cirrhosis, 2010
Cited by (1)
-
29
- Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy
-
IDE T
Hepatol Int 4, 594-600, 2010
Cited by (1)
-
30
- Current treatment for chronic hepatitis B in Japan
-
OHISHI W
Clin J Gastroenterol 2, 325-330, 2009
Ichushi Web Cited by (2)
-
31
- Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan
-
KUMADA Hiromitsu , OKANOUE Takeshi , ONJI Morikazu , MORIWAKI Hisataka , IZUMI Namiki , TANAKA Eiji , CHAYAMA Kazuaki , SAKISAKA Shotaro , TAKEHARA Tetsuo , OKETANI Makoto , SUZUKI Fumitaka , TOYOTA Joji , NOMURA Hideyuki , YOSHIOKA Kentaro , SEIKE Masataka , YOTSUYANAGI Hiroshi , UENO Yoshiyuki , The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis Ministry of Health Labor and Welfare of Japan
Hepatol Res 40(1), 1-7, 2010-01-01
Ichushi Web References (11) Cited by (17)
-
32
- Management of hepatitis B : consensus of the Japan Society of Hepatology 2009
-
YOKOSUKA O
Hepatol Res 41(1), 1-21, 2011
Ichushi Web Cited by (6)
-
33
- Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy
-
MATSUMOTO A
Hepatol Res 37, 661-666, 2007
Ichushi Web Cited by (9)
-
34
- Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders : Randomized controlled trial
-
MATSUURA Kentaro , TANAKA Yasuhito , KUSAKABE Atsunori , HIGE Shuhei , INOUE Jun , KOMATSU Masashi , KURAMITSU Tomoyuki , HIRANO Katsuharu , OHNO Tomoyoshi , HASEGAWA Izumi , KOBASHI Haruhiko , HINO Keisuke , HIASA Yoichi , NOMURA Hideyuki , SUGAUCHI Fuminaka , NOJIRI Shunsuke , JOH Takashi , MIZOKAMI Masashi
Hepatol Res 41(6), 505-511, 2011-06-01
Ichushi Web References (30) Cited by (2)
-
35
- Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance
-
Tanaka E , Matsumoto A , Suzuki F , Kobayashi M , Mizokami M , Tanaka Y , Okanoue T , Minami M , Chayama K , Imamura M , Yatsuhashi H , Nagaoka S , Yotsuyanagi H , Kawata S , Kimura T , Maki N , Iino S , Kiyosawa K
LIVER INTERNATIONAL 26(1), 90-96, 2006-02